Brokerages Set Repligen Co. (NASDAQ:RGEN) Price Target at $190.25

Repligen Co. (NASDAQ:RGEN - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the ten analysts that are presently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $190.25.

A number of brokerages recently issued reports on RGEN. UBS Group decreased their price target on shares of Repligen from $205.00 to $185.00 and set a "buy" rating for the company in a research note on Wednesday, July 31st. Stephens restated an "overweight" rating and set a $170.00 price objective on shares of Repligen in a research report on Tuesday, July 30th. Benchmark restated a "hold" rating on shares of Repligen in a research report on Monday, August 5th. JPMorgan Chase & Co. boosted their price objective on shares of Repligen from $190.00 to $200.00 and gave the stock an "overweight" rating in a research report on Wednesday, July 31st. Finally, Wells Fargo & Company assumed coverage on shares of Repligen in a research report on Tuesday, August 27th. They set an "overweight" rating and a $180.00 price objective for the company.

Repligen Trading Down 1.7 %

Shares of RGEN traded down $2.34 during trading on Tuesday, reaching $134.87. 462,397 shares of the company traded hands, compared to its average volume of 662,518. Repligen has a twelve month low of $110.45 and a twelve month high of $211.13. The stock has a market cap of $7.55 billion, a PE ratio of -3,429.39, a price-to-earnings-growth ratio of 3.91 and a beta of 0.95. The stock has a 50-day simple moving average of $143.12 and a 200-day simple moving average of $146.56. The company has a quick ratio of 5.56, a current ratio of 6.65 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings results on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share for the quarter, meeting analysts' consensus estimates of $0.33. Repligen had a negative net margin of 0.32% and a positive return on equity of 3.36%. The business had revenue of $154.07 million during the quarter, compared to analysts' expectations of $154.11 million. During the same period last year, the business earned $0.53 earnings per share. The business's revenue for the quarter was down 3.2% on a year-over-year basis. On average, analysts anticipate that Repligen will post 1.45 earnings per share for the current year.

Insider Activity

In other news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the transaction, the director now directly owns 139,840 shares of the company's stock, valued at $20,328,540.80. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Repligen news, VP Ralf Kuriyel sold 4,465 shares of the business's stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $165.67, for a total value of $739,716.55. Following the transaction, the vice president now directly owns 19,261 shares of the company's stock, valued at approximately $3,190,969.87. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Anthony Hunt sold 22,191 shares of the business's stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the transaction, the director now directly owns 139,840 shares in the company, valued at $20,328,540.80. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.20% of the company's stock.

Hedge Funds Weigh In On Repligen

Institutional investors have recently bought and sold shares of the company. Andra AP fonden acquired a new position in Repligen in the 2nd quarter valued at $25,000. Lazard Asset Management LLC boosted its position in shares of Repligen by 206.1% during the 1st quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company's stock worth $36,000 after purchasing an additional 136 shares in the last quarter. UMB Bank n.a. boosted its position in shares of Repligen by 138.3% during the 3rd quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company's stock worth $33,000 after purchasing an additional 130 shares in the last quarter. Blue Trust Inc. boosted its position in shares of Repligen by 113.4% during the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company's stock worth $36,000 after purchasing an additional 127 shares in the last quarter. Finally, International Assets Investment Management LLC purchased a new stake in shares of Repligen during the 2nd quarter worth $33,000. 97.64% of the stock is owned by institutional investors and hedge funds.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.